MedTrace Logo

Relation of Catechol-O-methyltransferase (COMT) Genotype and Response to Cognitive Remediation Schizophrenia

NCT00664274 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 142

Last updated 2015-04-17

No results posted yet for this study

Summary

This project will explore the relationship between catechol-O-methyltransferase (COMT) Val158/108Met genotype and response to a 12-week computerized neurocognitive rehabilitation (CRT) given to chronic schizophrenic patients.

Conditions

  • Chronic Schizophrenia

Interventions

BEHAVIORAL

Cognitive remediation therapy

36 sessions of Computerized Cognitive Skills Training, 3 per week for 12 weeks.

GENETIC

COMT Genotyping

One time saliva sample is taken to genotype catechol-O-methyltransferase Val158/108Met alleles.

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • Albert Einstein College of Medicine

    collaborator OTHER

  • Manhattan Psychiatric Center

    lead OTHER

Principal Investigators

  • Jean-Pierre Lindenmayer, M.D. · Manhattan Psychiatric Center

  • Herbert Lachman, M.D. · Albert Einstein College of Medicine

  • Susan Mc Gurk, PhD · New Hampshire-Dartmouth Psychiatric Research Center

  • Anzalee Khan, PhD · Manhattan Psychiatric Center

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-04-30
Primary Completion
2015-01-31
Completion
2016-10-31

Countries

  • United States

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00664274 on ClinicalTrials.gov